CR7660A - DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE - Google Patents
DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSEInfo
- Publication number
- CR7660A CR7660A CR7660A CR7660A CR7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A CR 7660 A CR7660 A CR 7660A
- Authority
- CR
- Costa Rica
- Prior art keywords
- composition
- hours
- average
- pramipexole
- absorption
- Prior art date
Links
Abstract
Se refiere a una composicion farmaceutica administrable oralmente que comprende una cantidad terapeuticamente eficaz de pramipexol o una de sus sales farmaceuticamente aceptable y al menos un excipiente farmaceuticamente aceptable, presentando dicha composicion al menos (a) un perfil de liberacion in vitro en el que en promedio no mas de 20% aproximadamente de pramipexol se disuelve en 2 horas despues de la colocacion de la composicion de ensayo de disolucion convencional, y (b) un perfil de absorcion de pramipexol in vivo despues de la administracion oral de una dosis a humanos adultos sanos, donde el tiempo para alcanzar una media de 20% de absorcion es mayor que 2 horas aproximadamente y/o el tiempo para alcanzar una media de 40% de absorcion es mayor que 4 horas aproximadamente. La composicion es util para administrarse oralmente no mas de una vez al dia a un sujeto que tenga una condicion o desorden para el cual sea indicado un agonista receptor de dopamina.It refers to an orally administrable pharmaceutical composition comprising a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition having at least (a) an in vitro release profile in which on average no more than about 20% of pramipexole dissolves in 2 hours after the placement of the conventional dissolution test composition, and (b) an absorption profile of pramipexole in vivo after oral administration of a dose to healthy adult humans , where the time to reach an average of 20% absorption is greater than about 2 hours and / or the time to reach an average of 40% absorption is greater than about 4 hours. The composition is useful for oral administration no more than once a day to a subject who has a condition or disorder for which a dopamine receptor agonist is indicated.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39842702P | 2002-07-25 | 2002-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR7660A true CR7660A (en) | 2005-06-08 |
Family
ID=38181237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR7660A CR7660A (en) | 2002-07-25 | 2005-01-24 | DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE |
Country Status (2)
Country | Link |
---|---|
CR (1) | CR7660A (en) |
TN (2) | TNSN05019A1 (en) |
-
2005
- 2005-01-24 CR CR7660A patent/CR7660A/en not_active Application Discontinuation
- 2005-01-25 TN TNP2005000019A patent/TNSN05019A1/en unknown
- 2005-01-25 TN TNP2005000020A patent/TNSN05020A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TNSN05020A1 (en) | 2007-05-14 |
TNSN05019A1 (en) | 2007-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040682A1 (en) | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL | |
JP6659072B2 (en) | Melatonin agonist treatment | |
ES2577930T3 (en) | Triazine derivatives to delay the onset of type 1 diabetes | |
AR040681A1 (en) | COMPOSITION OF PRAMIPEXOL SUSTAINED RELEASE TABLETS | |
AR045972A1 (en) | FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS | |
ES2579857T3 (en) | Platelet rich plasma compositions | |
AR062320A1 (en) | FLIBANSERIN FORMULATIONS AND METHOD TO MANUFACTURE THEM | |
UY27627A1 (en) | AZA - ARILPIPERAZINAS | |
SE0203065D0 (en) | Gastric acid secretion inhibiting composition | |
AR045289A1 (en) | ORAL DOSAGE FORM OF CONTROLLED RELEASE THAT INCLUDES 4- (2-DI-N-PROPILAMINOETIL) - 2 (3H) -INDOLONE (ROPI-NIROL) AND USE OF SUCH DOSAGE FORM FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
NO20073403L (en) | Use of atazanavir to improve the pharmacokinetics of drugs metabolized by UGT1A1 | |
AR040709A1 (en) | FORMULATION OF LAMOTRIGIN FOR LONG-TERM RELEASE AND USE OF THE SAME FOR PREPARATION | |
ATE505203T1 (en) | PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN | |
AR062659A1 (en) | COMPOSITION OF LEVODOPA SUSTAINED RELEASE AND METHOD FOR USE | |
CR7660A (en) | DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE | |
AR039162A1 (en) | VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION | |
AR046454A1 (en) | USE OF A BENZAZEPIN-N-ACETIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION, AND PROCEDURE FOR THE PRODUCTION OF THE PHARMACEUTICAL COMPOSITION | |
CO5680422A2 (en) | DOSAGE FORM OF PRAMIPEXOL IN A DAILY ONLY DOSE | |
Fava | The combination of buspirone and bupropion in the treatment of depression | |
Sayar et al. | Girls Like to Chat with me If There is a Piece of Bupropion Under My Tongue | |
WACHTER | Selegiline Safe, Effective as Adjunct for Parkinson’s | |
TH87764B (en) | The dosage form of Pramipec Sol is once a day. | |
JP2009084253A (en) | Prophylactic and/or therapeutic drug for headache | |
ECSP055749A (en) | FORMULATION OF SUSTAINED RELEASE TRAILER WITH EFFECTIVENESS OF 24 HOURS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC90 | Suspension of granting procedure |